ApoA-I输注与急性心梗后缺血事件总负担:AEGIS-II试验分析
AEGIS-II预设探索性分析纳入18,219例高危急性心梗患者,随机接受每周4次6g CSL112或安慰剂。CSL112未显著减少90天首个心血管死亡、心梗或卒中,但负二项回归显示180天和365天非致死性缺血事件与心血管死亡总事件数名义显著减少。
要点
- CSL112未显著减少90天首个CV死亡、MI或卒中事件。
- 180天和365天总缺血事件负担名义显著降低。
- 排除2型MI后各时间点非致死性MI和CV死亡总事件显著减少。
核心结论
- 在高危AMI患者中,每周4次6g CSL112输注在180天和365天显著减少非致死性缺血事件和心血管死亡的总负担。
研究设计与样本
- AEGIS-II试验的预设探索性分析,纳入18,219例AMI、多支冠状动脉病变且合并其他心血管危险因素的患者。
- 患者随机接受每周4次6g CSL112(n=9,112)或匹配安慰剂(n=9,107)。
- 采用负二项回归模型估计CSL112相比安慰剂对缺血事件发生率比(RR)的影响。
主要发现
- 90天CV死亡、MI和卒中总事件数:503 vs 545,RR 0.88(95%CI 0.76-1.03,P=0.11)。
- 180天总事件数:745 vs 821,RR 0.87(95%CI 0.77-0.99,P=0.04)。
- 365天总事件数:1,120 vs 1,211,RR 0.89(95%CI 0.80-0.99,P=0.04)。
- 后续事件占90天事件的13%、180天的17%、1年的22%。
- 排除2型MI后,非致死性MI和CV死亡总事件各时间点均名义显著减少:90天RR 0.81(95%CI 0.68-0.97,P=0.02);180天RR 0.82(95%CI 0.71-0.95,P<0.01);365天RR 0.86(95%CI 0.76-0.98,P=0.02)。
临床怎么用
- 对于高危AMI后患者,CSL112可能降低长期累积缺血事件负担,但需等待进一步验证。
- 评估干预效果时应关注总事件负担而非仅首个事件,后续事件占比随时间增加。
局限性
- 该分析为预设探索性分析,结果需谨慎解读。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Following an acute myocardial infarction (AMI), patients remain at risk for subsequent cardiovascular (CV) events. In the AEGIS-II trial, CSL112, a human apolipoprotein A-I derived from plasma that enhances cholesterol efflux, did not significantly reduce the first occurrence of CV death, myocardial infarction (MI), or stroke through 90 days compared with placebo. However, an analysis involving only the first event may not capture the totality of the clinical impact of an intervention because patients may experience multiple events. OBJECTIVES: This prespecified exploratory analysis examines the effect of CSL112 on total burden of nonfatal ischemic events (ie, recurrent MI and stroke) and CV death. METHODS: A total of 18,219 patients with AMI, multivessel coronary artery disease, and additional CV risk factors were randomized to either 4 weekly infusions of 6 g CSL112 (n = 9,112) or matching placebo (n = 9,107). A negative binomial regression model was applied to estimate the effect of CSL112 compared with placebo on the rate ratio (RR) of ischemic events. RESULTS: For CV death, MI, and stroke, there were numerically fewer total events at 90 days (503 vs 545 events; rate ratio [RR]: 0.88; 95% CI: 0.76-1.03, P = 0.11), and nominally significantly fewer total events at 180 days (745 vs 821 events, RR: 0.87; 95% CI: 0.77-0.99; P = 0.04) and 365 days (1,120 vs 1,211 events; RR: 0.89; 95% CI: 0.80-0.99; P = 0.04). Subsequent events constituted 13% of events at 90 days, 17% at 180 days, and 22% at 1 year. Similar findings were seen with the total occurrence of nonfatal MI and CV death. When type II MIs, unlikely to be modified by enhancing cholesterol efflux, were excluded, there were nominally significant reductions in the total occurrence of nonfatal MI (excluding type 2) and CV death at all time points (90 days: RR: 0.81; 95% CI: 0.68-0.97; P = 0.02; 180 days: RR: 0.82; 95% CI: 0.71-0.95; P < 0.01; 365 days: RR: 0.86; 95% CI: 0.76-0.98; P = 0.02). CONCLUSIONS: In this prespecified exploratory analysis of the AEGIS-II trial, 4 weekly infusions of CSL112 among high-risk patients after AMI significantly reduced the total burden of nonfatal ischemic events and CV death at 180 and 365 days compared with placebo. (AEGIS-II [Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome]; NCT03473223).
引用
- Gibson, Chi, Duffy, et al. ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II Trial. J Am Coll Cardiol. 2024. PMID: 39230545. doi:10.1016/j.jacc.2024.08.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。